can significantly decrease susceptibility, leading to antiviral resistance. From 2007 to 2008, oseltamivir-resistant strains that possessed H275Y mutations in their NA proteins began to emerge within seasonal H1N1 viruses 3 . Before 2009, the percentage of oseltamivir-resistant viruses in all subtypes, including seasonal H1N1, was no more than 1% [4] [5] [6] . Surprisingly, the prevalence of oseltamivir-resistant seasonal influenza H1N1 viruses increased to almost 100% between 2009 and 2010, even in countries where people had never used oseltamivir 7 . In contrast, influenza A H3N2 and seasonal B viruses remained sensitive to NAIs 8 . The emergence and worldwide spread of oseltamivir-resistant seasonal H1N1 viruses attracted considerable concern 9, 10 . Furthermore, in 2009, seasonal H1N1 viruses resistant to both amantadine and rimantadine were detected in several countries 11, 12 , including in China, and particularly in HongKong and Guangdong [12] [13] [14] . In March and early April of 2009, pandemic A H1N1 2009 viruses emerged in Mexico and the United States, respectively, and then spread rapidly all over the world. Subsequently, oseltamivir-resistant seasonal A H1N1 viruses were replaced by pandemic H1N1 viruses. WHO received the first report regarding an oseltamivir-resistant H1N1pdm2009 isolate in July 2009 15 , and the H275Y mutation within NA was detected in the drug-resistant virus. During the 2009-2010 influenza season, although the use of oseltamivir increased more than ever, oseltamivir-resistant H1N1pdm2009 viruses were reported only sporadically 16, 17 , with no cases reported in China. China began using neuraminidase inhibitors later than many other countries, so there are few studies on antiviral resistance. Virological and epidemiological surveillance remains critical for the detection of evolving influenza viruses. In order to survey the susceptibility of circulating strains in Guangdong to oseltamivir and to determine whether amino acid sequence variations may have had an impact on antiviral susceptibility, the Guangdong CDC launched an unprecedented surveillance of influenza H1N1pdm2009, A(H3N2) and B viruses, and these circulating strains (from 2009 to 2014) were compared to the wild-types and reference viruses. The study provided valuable information regarding the prevention and management of Guangdong human influenza.
Results
Temporal distribution trend. Amongst the 21 sentinel CDC centres in the Guangdong province, there were spring through summer seasonal influenza peaks every February through September. This seasonal outbreak is different from what occurs in Northern China and in the same latitude regions of America where the influenza activity peaks have occurred in winter months (December-January) 18, 19 . Furthermore, the predominant influenza virus types/subtypes based on isolates from clinical specimens were different for each season during the 63-month surveillance period. As shown in were isolated for influenza viruses with MDCK and further subtype. Five color columns represented for the number of five subtype isolates which distributed in different month, respectively. The blue column stands for the number of H7N9 strains, the purple column stands for the number of seasonal A(H1N1) strains, the green column stands for the number of seasonal B strains, the yellow column stands for the number of seasonal A(H3N2) strains, the red column stands for the number of A(H1N1) pdm09 strains.
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The outbreak of A/H7N9 infections occurred in Guangdong during the Spring of 2014. The numbers of isolated influenza viruses are listed in Table 1 .
Antiviral susceptibility of influenza viruses.
The susceptibility results for oseltamivir are summarized in Tables 2 and 3 . In total, 230 seasonal A (H3N2) viruses, 542 A(H1N1) pdm2009 viruses and 448 seasonal B viruses selected at random were subjected to NAI assays. Based on the WHO's definition of clinically oseltamivir-resistant, we found that no oseltamivir-resistant H1N1pdm viruses were isolated between 2009 and 2012. All seasonal influenza B viruses and H3N2 viruses tested from 2009 to 2014 were sensitive to oseltamivir. However, 5 of 198 tested H1N1pdm2009 isolates from 2013 were found to be resistant to oseltamivir. Similarly, 3 of 129 tested H1N1pdm isolates from 2014 were found to be resistant. Interestingly, some of the resistant variants had a more than 1000-fold increase in their IC 50 values for oseltamivir compared to those of the sensitive viruses ( Table 2) .
The eight tested oseltamivir-resistant H1N1 pdm2009 viruses had IC 50 values of 504 nM, 241 nM, 164 nM, 285 nM, 281 nM, 474 nM, 259 nM and 334 nM, respectively, as shown in Table 2 . IC 50 values for oseltamivir for the randomly tested isolates (x ± SD, nM). "-" = "Not determined". Computational structural analysis of the NA mutations. To investigate whether amino acid mutations affect the susceptibility of A(H1N1)pdm09 viruses to oseltamivir or may be responsible for reinforcing the oseltamivir-resistant effect, a computational structural analysis of NA substitutions was conducted. In this work, homology modeling and mocular docking methods were applied. Firstly, highly homologous NA crystal structure was retrieved from PDB Database, and then NA mutations investigated were introduced separately or as cumulative combinations using FoldX, on this basis, accurate three-dimensional space structures of these mutants were constructed using Modeller 9.x software. After that, the mocular docking between ligand (oseltamivir) and recepters (NA mutants) were performed using AutoDock softwares. Finally, the molecular dynamics simulations and the interaction forces between oseltamivir and NA mutants were calculated using Amber 14 and GAMESS softwares.
No matter how, what we need to clarify was, in this study we found that many mutation sites existed in NA of sensitive and resistant strains from 2009-2014, but in fact just a few of them affect the susceptibility or resistance of NA to oseltamivir based on the systematic analysis of various NA structures. For example, the analysis found that Asn44 was far away from the binding pocket of oseltamivir, and all NA crystal structures reported had not the N-terminal peptide fragment. So in this study, the N-terminal peptide was not constructed into the stucture models, as well as N44S mutation. In addition, although the mutation of I321 residue happened in the NA variants, it had not remarkable effect to the whole conformation changes. A local hydrophobic core was composed of I321, I359, I374 and F387, which formed a very compact hydrophobic center. Even the I321V mutations existed in NA variants, the little difference of side chain between I and V can be adapted by hydrophobicity, the mutation did not force this hydrophobic core to change its conformation. So in this study, we pay more discussion on NA-V241I, N369K, N386K and K432E substitutions due to their potential role on susceptibility.
For mutation V241I, sequence alignments analysis showed that V241I substitutions almost occurred in all resistant and sensitive strains circulating between the 2012-2014. Anyway, this mutation resulted in a longer side-chain and made it easier to interact with Phe306 through ahydrophobic effect, which shifted side-chains of His275 and Glu277 by 0.8 Å and 2.5 Å, respectively. At the same time, Asp151, located on the other side of the active pocket, shifted approximately 1.6 Å away from oseltamivir, and the distance between Asp151 and oseltamivir increased from 2.6 Å to 6.8 Å (Fig. 3) . It was obvious that the latter shift strongly weakened the interaction between the -NH 2 of oseltamivir and the COO − of Asp151 (Fig. 3) . If V241I existed in conjunction with H275Y, the side-chains of these residues would shift more than V241I alone. Thus, the binding pocket was elongated along the direction from H275 to D151, which makes the interaction of this key hydrogen bond weaker (Fig. 3) .
Another two important substitutions were N369K and K432E, as both single and double mutations. Along with Arg368 and Lys432, the N369K mutation made the local electrical density of NA more positive. The stronger positive electrostatic field made NA more susceptible to oseltamivir due to the negatively-charged COO − side chain in this drug. If N369K and K432E both occurred in NA, this positive electrostatic field would be broken, and the mutated E432 would be able to form a salt bridge with K369 (Fig. 4) . This pair of interactions was found in the simulated complex. The strong salt bridge effect even shifted the side chain of Trp399 outward approximately 4.4 Å, close to the K432E mutation. In addition, the double mutation (N369K and K432E) made the binding pocket contract slightly and the oseltamivir conformation rotate approximately 35.1 degrees (Fig. 4) .
For mutation N386K, significant changes within the side chain electrical properties would lead to a series of conformational changes. Although close to Asp384, the positive-charged K386 showed a stronger attraction to Asp384 and obvious conformational connections with the flexible loops of N378-S388 and P328-C335, as well as S339-G345. These connections could alter the susceptibility of oseltamivir to influenza viruses to a certain extent. As mentioned above, V241I made the binding pocket longer along residues H275 to D151. In addition, the V241I and N386K double mutation, which existed in most strains isolated from the Influenza Surveillance Network Platform of Guangdong Province, resulted in a synergistic effect within the binding pocket for oseltamivir. Thus, the N386K mutation, in combination with V241I, elongated the binding pocket while pushing several loops outward. The affected residues include R368, E119, D151 and R152, which formed stronger interactions with the -COO − , NH 2 and -COCH 3 groups of oseltamivir (Fig. 5 ).
Discussion
In . Given the high mortality of H7N9 infections, the early strategy to treat patients was oseltamivir. Although there was not one infection to be found in Guangdong before July 2013, using poultry and environmental surveillance in live poultry markets, we found that chickens had been infected with the H7N9 virus and were being sold in markets in cities within Guangdong in April and May 2013 21 . In May 2013, the public health bureau of Guangdong province asked the public health system to carry out enhanced ILI surveillance to discover the H7N9-infected individual early and prepare enough oseltamivir to treat potential cases. From the surveillance data, we found that oseltamivir-resistant A(H1N1)pdm2009 strains appeared only two months later. In other words, following the Guangdong province outbreak in 2009, oseltamivir-resistant A(H1N1)pdm2009 was not detected until June 2013. The surveillance results suggested that the emergence of resistant H1N1pdm2009 strains may be due to the increased use of oseltamivir after the H7N9 influenza outbreak. The correlation can be seen from Fig. 1 . The fact of the increased use of oseltamivir after H7N9 epidemic also can be confirmed by the China official guidelines for diagnosis and treatment of H7N9 influenza.The guidance suggested treatment with antivirals for patients with confirmed, probable, or suspected avian influenza A(H7N9), and for individuals who are at increased risk for influenza-related complications. Moreover, the patients with influenza-like illness and normal or lower white blood cells, individuals who are at high risk for severe illness from avian influenza A(H7N9) should be given antiviral treatment as soon as possible. In a word, the guidelines emphasized early use of antiviral treatment for avian influenza A(H7N9), oseltamivir is strongly Figure 5 . Loop rearrangement of NA resulting from the N386K mutation. The N386/K386 and D384 residues are labelled by colour element representations. The short loops are indicated by the red and green cartoons, which are directly affected by this mutation. Most loops located at binding sites conform to allow for a larger space, while the Y275 residue can shift a little ways from the bound ligand. These loop rearrangements will ultimately decrease the affinity of the ligand for NA.
Scientific RepoRts | 7: 8488 | DOI:10.1038/s41598-017-08282-6 recommended for early treatment of suspected or confirmed avian influenza A(H7N9) or other severe influenza cases 22 . Oseltamivir exerts the inhibitory effect through its active metabolite oseltamivir carboxylate(OC) recognizing and binding to the active domain of NA. Resistance to oseltamivir is caused primarily by the mutations of amino acid residues in NA domain which changed the binding affility. The H275Y mutation that confers resistance to oseltamivir has been detected in various human influenza N1 subtypes, including seasonal H1N1 9, 23-26 , highly pathogenic H5N1 27, 28 and, more recently, A(H1N1)pdm2009 viruses [29] [30] [31] [32] [33] . It is well known that H275Y confers very strong resistance. Once the H275Y mutation appears, the sensitivity of the A(H1N1)pdm2009 clinical isolates to oseltamivir can decrease by 1466-fold when compared to that of wild-type 25 . There have been many studies on the resistance mechanism of NA-H275Y mutation A(H1N1)pdm2009 strains to oseltamivir 34, 35 . In this study, we surveyed the susceptibility of circulating strains in Guangdong during the 2009-2014 to oseltamivir by phenotypic and genotypic test. As a result, we detected out eight osetamivir-resistant A (H1N1)/ pdm2009 viruses from the 2013/2014 isolates. It was also the first time that osetamivir-resistant strains were discovered in Guangdong, China in June 2013 since A(H1N1)/pdm2009 worldwide pandemic. Further findings presented that all of eight oseltamivir-resistant strains occurred N44S, N200S, V241I, H275Y and N369K mutations in common, among these, there are three strains possessing NA-I321V, N386K and K432E mutations. Anyway, it have been previously reported that A(H1N1)pdm09 mutation viruses possessed N44S, V106I, N200S, I223R/V, V241I, S247N, N369K and N386K substitutions in the NA gene. With regard to these site mutations, there also have been some study reports on their potential effects [36] [37] [38] [39] . For example, NA-S247N and I223R/V mutations in A(H1N1)pdm09 influenza viruses can confer reduced susceptibility to oseltamivir. A novel A(H1N1)pdm09 variant containing NA-S247N mutation was found mainly in the Asia-Pacific area in recent years. This mutation reduces sensitivity and confers extremely high resistance to oseltamivir in combination with the H275Y mutation when compared to resistance conferred by the H275Y mutation alone 40, 41 . Likewise, when compared to the wild-type strains, clinical isolates with NA-I223R mutations had an approximately two-fold reduced affinity for the substrate; the isolates containing H275Y-and I223R-also showed decreased susceptibility to oseltamivir(246-fold) 42, 43 . In addition, the other NA substitutions, like as V241I, N369K and N386K, which were presented in the oseltamivir-resistant strains studied here, may offset the destabilizing effect of the H275Y substitution. Particularly, the N369K mutation, which was computationally predicted to cause the largest change in NA protein stability, has previously been shown experimentally to increase NA surface expression and activity in combination with H275Y 44 . In this work, we applied computational analysis methods to discuss whether the binding affinity between NA and oseltamivir will happen to change when NA occurred V241I, N369K, N386K and K432E mutations, alone or in combination with H275Y, and further have a impact on susceptibility of A(H1N1)pdm09 strains to oseltamivir. Anyway, it stands from another new perspective to analysis and interpret the potential correlation between phenotype and genotype.
However, the computational structural analysis showed that some amino acid residues, like as I34V, N44S, I106V, N200S and I321V, are not located in the oseltamivir-binding domain of NA. So in this work, the analysis primarily focused on mutations within the binding domains, including V241I, N369K, N386K and K432E. The results showed that the binding pocket of NA became narrower upon mutation of N369 and K432 (N369K and K432E), so that the binding angles changed approximately 35.1 degrees, which led to decreased binding of oseltamivir to NA. The V241I mutation almost was presented in all resistant and sensitive strains circulating between the 2012-2014. If NA-V241I mutation emerged in conjunction with H275Y, they will generate the synergy effect in the highly reduced sensitivity of viruses to oseltamivir. In addition, the binding ability of oseltamivir to NA also decreased when mutations V241I and N386K were present. On balance, the obtained results revealed that V241I, N369K, N386K and K432E mutations may alter the susceptibility of A(H1N1)pdm09 variants to oseltamivir.
Apart that, the current study revealed that the NA-V241I/N369K/N386K/K432E mutation in conjunction with the H275Y substitution had emerged in the 2013/2014 resistant variants in Guangdong, China. Furthermore, sensitive strain, like as A/Guangdong/452/2014 strain, also possessed NA-V241I/N369K/N386K/ K432E quadruple mutation. Noticeably, A/Guangdong/452/2014 strain have a relative higher IC50 (1.44 nM) than the IC50 average value 0.54 nM of sensitive strains. We thought that this should not be occasional. Although A(H1N1)pdm09 viruses with the mutations NA-V241I, N369K, N386K and K432E are not clinically defined as oseltamivir-resistant strains according to the definition of the WHO, its greater reduction in susceptibility to oseltamivir (2.67-fold increase in IC 50 ) suggested that these substitutions may have contributed for the significantly higher IC50 values obtained, compared to wild-type viruses.
In conclusion, the current studies suggest that V241I, N369K, N386K and K432E mutations, alone or in combination with H275Y, may change the binding affinity between oseltamivir and NA, and further have a impact on susceptibility of A(H1N1)pdm09 strains to oseltamivir. So the emergence of such variants should be carefully monitored for public health concerns. It's very obvious that our study results in general were coincided with the current reported views. Anyway, the obtained results will contribute to supplement scientific literature on the susceptibility of predominant circulating influenza virus to oseltamivir, particularly, for the global assessment of A(H1N1)pdm09 virus susceptibility profile and baseline level to NAIs.
Materials and Methods
Clinical specimen collection and influenza virus subtyping. In our experiments, influenza A(H1N1) pdm2009 and seasonal A(H3N2) and B viruses were obtained through the influenza-like illness(ILI) surveillance system of the Guangdong Provincial Centre for Disease Control and Prevention. This network is composed of 21 representative municipal CDCs. Each CDC selected one or several sentinel hospitals located in their respective cities. These hospitals were selected based on regional representation and demonstrated capacity to conduct ILI surveillance. Sentinel hospitals collected nasopharyngeal swabs from patients according to a standard procedure, and the swabs were kept in viral transport medium and stored at 4 °C for up to 24 hours prior to analysis. Virus isolation was prepared in physical containment level 2 biosafety facilities by culturing in MDCK cells and embryonated SPF (specific pathogen-free) eggs. Influenza virus subtyping was performed according to the serological methods of the National Standard Operating Procedures (SOP).
Drugs. Oseltamivir (Ro64802002) were kindly donated by F. Hoffmann-La Roche Ltd., Basel, Switzerland. The drugs were dissolved in MilliQ water to a final concentration of 5 μM and stored at −20 °C.
Influenza virus isolation with MDCK cell lines.
In this experiment, MDCK (ATCC, USA) cell lines passaged 3-50 times were used. MDCK cells (10 5 /ml) were seeded in T25 flasks with DMEM(Hyclone, USA) containing 10% Fetal Bovine Serum(FBS, Hyclone, USA) and 1% penicillin-streptomycin(Sigma, USA) in a final volume of 6 mL and then incubated at 37 °C in a humidified air atmosphere with 5% CO 2 for 48 hours. When the cells reached 70-90% confluence, the culture medium was discarded, and the cells were washed three times with Hank's solution. After the culture medium was removed, an appropriate amount of clinical specimen was added into the flask with a sterile pipette. Subsequently, the flasks were gently shaken and then incubated at 37 °C in a humidified air atmosphere with 5% CO 2 for one or two hours to allow for virus absorption. The infected cells were again washed twice with Hank's solution after removing the inoculum. Finally, the prepared virus growth medium was added to the flasks, and the cells were incubated at 33-35 °C. The cell culture was observed daily for cytopathic and morphological changes using an inverted light microscope. The culture supernatant was harvested when 75-100% of the infected cells appeared to be cytopathic and stored at −80 °C.
NAI susceptibility.
A fluorescence-based neuraminidase inhibition assay using the fluorescence substrate 2′-(4-methylumbelliferyl)-α-D-N-acetyl neuraminic acid (4-MU-NANA; Sigma, St. Louis, MO) was performed in accordance with international Standard Operating Procedures(SOP) to measure influenza virus neuraminidase (NA) activity in the presence of oseltamivir.Hydrolysis of the α-ketosidic bond in 4-MU-NANA by NA releases the fluorescent indicator 4-MU. Oseltamivir was added at the intended concentrations. The NAI susceptibility of influenza viruses was characterized by using oseltamivir concentrations that inhibited NA activity by 50%(IC 50 ) as described previously 45 . As defined by the WHO, influenza A viruses with normal inhibition (NI) have a < 10-fold increase in IC 50 .Viruses with reduced inhibition (RI) have a 10-to 100-fold increase in IC 50 . Viruses showing highly reduced inhibition (HRI) are those with a > 100-fold increase in IC 50 , these viruses are considered clinically resistant. Oseltamivir-resistant viruses were defined as influenza viruses having IC 50 values greater than 100 nM 9 .
Primer design. NA, HA and M2 primers for H1N1pdm2009 were designed according to the results of the NAI susceptibility assay. The genes for NA, HA and M2 were amplified with 2-3 overlapping PCR segments to ensure that good quality sequencing data could be obtained from both directions on one segment. The specific primers were as follows: NA: 5′-ATGAATCCAAACCAAAAG-3′(forward), 5′-TTACTTGTCAATGGTAAATGG-3′(reverse); HA: 5′-ATGAAGGCAACA CTAGTAG-3′(forward), 5′-TTAAATACATATTCTACACTG-3′(reverse); M2:5′-AGCACT ACAGCTAAGGCTATGG-3′(forward), 5′-AGTAGAAACAAGGTAGTTTTTTACTC-3′ (reverse). The product sizes of NA, HA and M2 were approximately 1410 bp, 1710 bp and 572-1027 bp, respectively. All primers were synthesized by Sangon Biotech(Shanghai, China). Sequencing and sequence analysis. Prior to sequencing, Sanger PCR(chain termination method) was performed using an ABI PRISM BigDye Terminator V1.1 Cycle Sequencing Kit (Applied Bio-systems, Foster City, CA, USA) and primers designed previously, with the amplicon as a template. The reaction mixture consisted of 0.5 μL of BigDye, 2 μL of 5× sequencing buffer, 1 µL of primer, 1 μL of template, and 5.5 μL of RNAase-free ddH 2 O in PCR tubes. PCR cycling conditions were as follows: one cycle of 1 min at 96 °C; 25 cycles of 10 seconds at 96 °C and 15 seconds at 50 °C; and a final extension at 60 °C for 4 min. The reaction products were purified using a BigDye X Terminator Purification Kit(Applied Biosystems, USA) and run on an ABI 3100XL sequencer (ABI, USA). Sequencing results were analysed using an ABI PRISM 3100 Genetic Analyzer (Applied Bio-systems, Foster City, CA, USA). The nucleotide and amino acid sequence data for NA of influenza A(H1N1)pdm2009 were retrieved from NCBI GeneBank and NCBI Influenza Sequence Database and BioEdit 7.0.9.0. In addition, sequence analysis of sensitive viruses was performed using SNP pyrophosphate detection.
Viral
Modelling and analysis of NA mutations. To understand a correlation between phenotype and genotype, and reveal whether amino acid substitutions at residue V241, N369, N386 and K432 of the neuraminidase (NA) protein in A(H1N1)pdm09 variants may alter susceptibilities to oseltamivir. So by the computational structural analysis methods, we analyzed A(H1N1)pdm09 variants from Guangdong, China during the 2009-2014. In the work, We performed homology modeling and mocular docking using Modeller 9.x and AutoDock software. Based on the results of NA sequencing and NAI susceptibility assays, the changes of binding affinities and conformations between NA and oseltamivir were analyzed, by taking that of wild-type A/California/04/2009 pandemic strains as a reference. Here, 4 structures with the PDB IDs 4B7Q, 3NSS, 4QNP and 4B7R were used as templates to construct the mutated NA proteins (V241I, H275Y, I321V, N369K, N386S, N386K and K432E, either alone or in combination). All modelled complexes were placed into similar physiological environments, and standard molecular dynamics (MD) simulations were performed to obtain stable conformations. The Amber 14 suite was used for all MD simulations, with the force-field parameters of oseltamivir calculated using Gaussian 09.
Statistical Analysis. SPSS 13.0 (SPSS Inc. Chicago, IL, USA) was employed for statistical analysis. IC 50 values were calculated using SPSS 13.0 software. Quantitative data are presented as the mean ± standard deviation(SD). The comparison of IC 50 values was conducted using analysis of variance(ANOVA) with a t-test or Levene test. Levels of significance were set at P < 0.05.
